Japanese Encephalitis Vaccine (JEV)
Pre-Solicitation Posted
- Solicitation number
- SPE2DP-23-R-0001
- Agency
- Medical Supply Chain Troop Support, Department of Defense
- Responses due
- Not on record
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support seeks to award a one-year firm-fixed-price indefinite quantity contract for the supply of Japanese Encephalitis Vaccine. The vaccine must be purified, inactivated, cell culture derived, FDA licensed and approved for administration to persons ages 2 months and older. The contract will have a minimum quantity of 201,600 doses and maximum of 300,160 doses to be delivered to the Defense Distribution Depot Susquehanna within 120 days of order. To be eligible for award, the offeror must have FDA approval to sell JEV. Solicitation SPE2DP-23-R-0001 will be issued on July 14, 2023 via the DIBBS system and proposals will be evaluated without using a set-aside.
The pre-solicitation notice does not specify a NAICS code, product service code, or identify any incumbent contractors. The contract has a base year value between $201,600 for the minimum quantity to $300,160 for the maximum, to be delivered FOB Destination within 120 days of order. The point of contact is listed as Danielle Delaney of the DLA Troop Support-FSA, who can be reached at 215-737-2998.
Notice text
The Defense Logistics Agency Troop Support has a requirement for the supply of Japanese Encephalitis Vaccine (JEV), NSN 6505-01-607-7018. The vaccine shall be purified, inactivated, Vero Cell culture derived, contain no stabilizers, Thimerosal/Preservative free, Latex free, licensed by the Food and Drug Administration (FDA), suitable for intramuscular administration and intended for active immunization against Japanese Encephalitis disease. The vaccine shall be a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle. The vaccine must be approved by the United States FDA for administration to persons 2 months and up.
The proposed contract will be a one (1) year base firm-fixed price indefinite quantity contract.
The requirement for the base year is 201,600 doses minimum and a maximum of 300,160 doses.
Ordered quantities shall be delivered to the Defense Distribution Depot Susquehanna. Delivery is to be FOB Destination and delivered within 120 days from date of the delivery order.
All responsible sources may submit a proposal and shall be considered by the Agency.
The successful contractor shall have FDA approval to sell JEV before award of the contract.
Solicitation SPE2DP-23-R-0001 is expected to be issued on or after July 14, 2023 and can be found on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. The point of contact is Danielle Delaney, DLA Troop Support-FSA, 215-737-2998.
The Solicitation will be issued under authority 10 U.S.C. 2034 (c) 1, only one responsible source.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Japanese Encephalitis Vaccine (JEV) | Pre-Solicitation | |
| Japanese Encephalitis Vaccine (JEV) | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity